Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

F. H. FAULDING ACQUIRING 40% STAKE IN MOLECULON with a $31 mil. investment in the Cambridge, Mass.-based controlled release R&D firm. A pharmaceutical manufacturer and distributor based in Australia, F.H. Faulding & Co. Ltd. also develops sustained release dosage forms. Parke-Davis' Eryc and Doryx are licensed from Faulding. In a Sept. 3 release, Moleculon said the arrangement with Faulding will "not only provide Moleculon with sufficient capital for the continued development of its proprietary transdermal products and the establishment of manufacturing capabilities, but should also provide Moleculon with Faulding's considerable experience in sustained-release formulations and marketing and manufacturing expertise." The relationship with the Australian firm, Moleculon noted, will also provide "further opportunities for collaborative research and development services with major pharmaceutical companies worldwide." Faulding is paying an amount roughly equivalent to Moleculon's stock market value prior to the announcement. At the stock's Sept. 2 closing price of 3-7/8, Moleculon carried a market valuation of approximately $30.7 mil. The stock jumped 1-1/8 to 5 on the day of the announcement and closed the week at 4-3/4. Moleculon currently has five transdermal products using the patented Poroplastic technology in clinical trials, including a chlorpheniramine patch developed for Bristol-Myers and an isosorbide patch for Wyeth-Ayerst Labs. The company has also commented on an agreement with Thompson Medical covering a transdermal phenylpropanolamine diet aid and a tiethanolamine salicylate analgesic patch. The first stage of the deal with Faulding involves the sale of 700,000 Moleculon shares to the Australian company for $3 mil. The second phase is "anticipated to occur in November 1987" and "entails the purchase of approximately 820,000 additional shares of Moleculon common and 834,000 shares of preferred stock for a total consideration of $28 mil.," Moleculon reported. In return, Faulding will get representation on Moleculon's board and operating management. Moleculon was formerly known as Moleculon Biotech.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts